Reviewing Ocular Therapeutix Inc. (OCUL)’s and Neuralstem Inc. (NASDAQ:CUR)’s results

Ocular Therapeutix Inc. (NASDAQ:OCUL) and Neuralstem Inc. (NASDAQ:CUR), both competing one another are Biotechnology companies. We will compare their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ocular Therapeutix Inc. 1.99M 77.49 59.98M -1.59 0.00
Neuralstem Inc. N/A 30.94 4.92M -0.52 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 has Ocular Therapeutix Inc. and Neuralstem Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Ocular Therapeutix Inc. -3,014.07% -133.7% -81.6%
Neuralstem Inc. 0.00% -123.1% -74.7%

Volatility & Risk

Ocular Therapeutix Inc. has a beta of 1.87 and its 87.00% more volatile than S&P 500. From a competition point of view, Neuralstem Inc. has a 2.62 beta which is 162.00% more volatile compared to S&P 500.


Ocular Therapeutix Inc.’s Current Ratio and Quick Ratio are 4.3 and 4.3 respectively. The Current Ratio and Quick Ratio of its competitor Neuralstem Inc. are 5.5 and 5.5 respectively. Neuralstem Inc. therefore has a better chance of paying off short and long-term obligations compared to Ocular Therapeutix Inc.

Analyst Ratings

Ocular Therapeutix Inc. and Neuralstem Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ocular Therapeutix Inc. 0 0 5 3.00
Neuralstem Inc. 0 0 0 0.00

Ocular Therapeutix Inc. has a 288.89% upside potential and a consensus price target of $14.

Institutional and Insider Ownership

Institutional investors held 53.6% of Ocular Therapeutix Inc. shares and 16.8% of Neuralstem Inc. shares. Insiders held 0.2% of Ocular Therapeutix Inc. shares. Competitively, 13.52% are Neuralstem Inc.’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ocular Therapeutix Inc. -1.26% 24.6% -16.78% -27.43% -14.52% 18.34%
Neuralstem Inc. 6.47% 16.4% 0.1% -58.3% -66.18% 59.85%

For the past year Ocular Therapeutix Inc. was less bullish than Neuralstem Inc.


Neuralstem Inc. beats Ocular Therapeutix Inc. on 7 of the 10 factors.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology. Its product pipeline candidates utilize its platform to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release one-time or several-month dosage forms. The companyÂ’s lead product candidate, DEXTENZA (dexamethasone insert) 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. It is also developing OTX-TP (travoprost insert), which is in Phase 3 clinical development for glaucoma and ocular hypertension. In addition, the company is evaluating injectable drug delivery depots for back-of-the-eye diseases. Further, its commercial product includes the ReSure Sealant, which has been approved by the Food and Drug Administration (FDA) for ophthalmic use. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companyÂ’s stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.